LyphoMed's bretylium tosylate
The injectable product in dosage of 100 mg/ml in a 10 ml vial (1,000 mg total drug content) is ANDA suitable, FDA said. Reference drug is LyphoMed's bretylium tosylate 50 mg/ml in a 10 ml vial (500 mg total drug content).
You may also be interested in...
Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.
A detailed report published by Medicines for Europe setting out policies affecting the off-patent industry across 22 European countries demonstrates the urgent need for pricing and reimbursement and procurement reforms, the association insists.
The Swiss major, which is already signed up to help produce Pfizer and BioNTech's COVID-19 vaccine, is offering its services to CureVac to produce its mRNA vaccine.